On January 8, 2023 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company focused on the development of novel antibody therapeutics, reported that it has entered into an exclusive option and license agreement with Radiance Biopharma Inc. ("Radiance"), a biotechnology company that specializes in the development of next-generation antibody-drug conjugates (Press release, Biocytogen, JAN 8, 2024, View Source [SID1234639130]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agreement grants Radiance an option to license from Biocytogen a first-in-class, fully human anti-HER2/TROP2 bispecific antibody drug conjugate (BsADC) for the development, manufacture and commercialization of therapeutic products for all human indications worldwide. HER2 and TROP2 are two tumor-associated antigens (TAAs) that are commonly expressed and co-expressed by various tumor types, including breast, gastric, colorectal, bladder, pancreatic, and non-small cell lung cancers.
Under the terms of the agreement, upon exercise of the option, Biocytogen will be entitled to an option fee, a royalty, development and commercialization milestone payments, and single-digit royalties on net sales. In addition, Biocytogen has the right to collect any sublicensing fee between Radiance and a third party.
Dr. Yuelei Shen, President and CEO of Biocytogen, said , " We are pleased to collaborate with Radiance, a strong team with extensive drug development experience, to develop a leading proprietary, fully human bispecific antibody-drug conjugate. We are optimistic that the combination of our strength in BsADC discovery and the extensive experience of the Radiance team will help accelerate the commercialization of this dual BsADC."
Marc Lippman, MD, Chairman of the Board of Radiance, said , " We are pleased to enter into this exclusive option and license agreement with Biocytogen for a novel human bispecific antibody-drug conjugate targeting HER2 and Trop2. Preclinical data from in vitro and in vivo testing with this BsADC show promising high potency of anti-tumor activities in leading tumor indications. We look forward to working with Biocytogen to bring the product into practice for the benefit of patients."